|
Senior Member
|
因為我爸是有心臟病、糖尿病、高血壓
不敢打AZ
莫德納、輝瑞的第二劑我認為風險沒有比較低
加上兩個都要等到9月多之後
所以我先改這樣
目前的證據我認為高端不會輸AZ
引用:
https://www.dynavax.com/science/cpg-1018/
CpG 1018
CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell memory responses.
Additionally, CpG 1018 strongly favors development of the Th1 subset of helper T cells, the type of helper T cell that is essential for protection from infections with viruses and intracellular bacteria. CpG 1018 targets a single, well defined receptor (TLR9) expressed on only a few key cell types and the mechanisms of action as an adjuvant are quite well understood.
CpG 1018 provides a well‑developed technology and a significant safety database, potentially accelerating the development of novel vaccines.
|
|